Risk factors associated with development of coinfection in critically Ill patients with COVID-19

Background: At outset of the coronavirus disease 2019 (COVID-19) pandemic, the significance of bacterial and fungal coinfections in individuals with COVID-19 was unknown. Initial reports indi-cated that the prevalence of coinfection in the general population was low, but there was uncer-tainty regarding the risk of coinfection in critically ill patients. Methods: Nine hundred critically ill adult patients with COVID-19 infection were enrolled in this observational case-control study. Patients with a coinfection (case) and patients without a coin-fection (control) were compared using univariate and multivariable analyses. A subgroup analysis was performed on patients with coinfection, dividing them into early (infection within 7 days) and late (infection after 7 days) infection groups. Results: Two hundred and thirty-three patients (25.9%) had a bacterial or fungal coinfection. Va-sopressor use (P < 0.001) and severity of illness (higher Acute Physiology and Chronic Health Evalu-ation III score, P=0.009) were risk factors for the development of a coinfection. Patients with coin-fection had higher mortality and length of stay. Vasopressor and corticosteroid use and central line and foley catheter placement were risk factors for late infection (> 7 days). There were high rates of drug-resistant infections. Conclusions: Critically ill patients with COVID-19 are at risk for both community-acquired and hospital-acquired infections throughout their hospitalization for COVID-19. It is important to con-sider the development of a coinfection in clinically worsening critically ill patients with COVID-19 and consider the likelihood of drug-resistance when choosing an empiric regimen.